Zymeworks (ZYME)
(Delayed Data from NSDQ)
$12.54 USD
-0.06 (-0.48%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $12.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Zymeworks Inc. has a market cap of $878.01M, which represents its share price of $12.60 multiplied by its outstanding shares number of 69.68M. As a small-cap company, ZYME's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ZYME 12.54 -0.06(-0.48%)
Will ZYME be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Other News for ZYME
Commit To Buy Zymeworks At $7.50, Earn 26.1% Annualized Using Options
Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance
Zymeworks (ZYME) Receives FDA Green Light for New Drug Targeting Liver Cancer
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel ...
Zymeworks announces FDA clearance of IND application for ZW251